Brokerages Set Gilead Sciences, Inc. (GILD) PT at $85.19
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been given an average recommendation of “Buy” by the thirty-three research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $83.94.
Several brokerages have commented on GILD. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 7th. Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Vetr cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 target price for the company. in a research report on Monday, September 4th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $83.00 target price (up previously from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th.
Gilead Sciences (NASDAQ:GILD) traded down $1.70 during mid-day trading on Friday, reaching $71.15. 10,925,301 shares of the company traded hands, compared to its average volume of 9,364,533. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $86.27. The company has a market cap of $93,630.00, a PE ratio of 7.60, a PEG ratio of -1.22 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.75 EPS. equities research analysts anticipate that Gilead Sciences will post 8.53 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.92%. Gilead Sciences’s payout ratio is 23.66%.
TRADEMARK VIOLATION NOTICE: “Brokerages Set Gilead Sciences, Inc. (GILD) PT at $85.19” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/brokerages-set-gilead-sciences-inc-gild-pt-at-85-19/1705653.html.
In other Gilead Sciences news, EVP Gregg H. Alton sold 50,000 shares of the stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now directly owns 113,237 shares of the company’s stock, valued at approximately $8,945,723. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 446,819 shares of company stock worth $36,269,486. 1.30% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in GILD. Lucas Capital Management raised its holdings in Gilead Sciences by 6.9% in the 1st quarter. Lucas Capital Management now owns 9,720 shares of the biopharmaceutical company’s stock valued at $660,000 after acquiring an additional 625 shares during the period. AT Bancorp raised its holdings in Gilead Sciences by 2.1% in the 1st quarter. AT Bancorp now owns 48,654 shares of the biopharmaceutical company’s stock valued at $3,305,000 after acquiring an additional 992 shares during the period. Solaris Asset Management LLC raised its holdings in Gilead Sciences by 3.4% in the 1st quarter. Solaris Asset Management LLC now owns 25,867 shares of the biopharmaceutical company’s stock valued at $1,757,000 after acquiring an additional 845 shares during the period. Strategic Advisors LLC bought a new position in shares of Gilead Sciences during the first quarter worth approximately $1,041,000. Finally, Point View Wealth Management Inc. increased its holdings in shares of Gilead Sciences by 21.4% during the first quarter. Point View Wealth Management Inc. now owns 7,851 shares of the biopharmaceutical company’s stock worth $533,000 after purchasing an additional 1,385 shares during the period. 74.62% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.